John Clapham

John Clapham is General Manager of BioTechnique, a contract manufacturing organization that specializes in manufacturing highly potent sterile injectable formulations. Headquartered in York, Pennsylvania, BioTechnique is driving the future of manufacturing innovation in producing essential medicines, including COVID-19 vaccines and boosters. BioTechnique has the goal of reducing U.S. over-reliance on foreign manufacturers of Active Pharmaceutical Ingredients (APIs) and excipients as well as increasing American advanced manufacturing jobs. BioTechnique expects to create as many as 250 jobs—much high quality—in the next three years.

Mr. Clapham is also the CEO of PSC Biotech, PSC Software, and Future Cures.